154 related articles for article (PubMed ID: 34334589)
1. Acromegaly Cases Exhibiting Increased Growth Hormone Levels during Oral Glucose Loading with Preadministration of Dipeptidyl Peptidase-4 Inhibitor.
Oba-Yamamoto C; Kameda H; Miyoshi H; Sekizaki T; Takase T; Yanagimachi T; Fujita Y; Nomoto H; Cho KY; Nakamura A; Nagai S; Atsumi T
Intern Med; 2021; 60(15):2375-2383. PubMed ID: 34334589
[TBL] [Abstract][Full Text] [Related]
2. MANAGEMENT OF ENDOCRINE DISEASE: Etiology and outcome of acromegaly in patients with a paradoxical GH response to glucose.
Hage M; Janot C; Salenave S; Chanson P; Kamenický P
Eur J Endocrinol; 2021 May; 184(6):R261-R268. PubMed ID: 33830942
[TBL] [Abstract][Full Text] [Related]
3. Glucose-dependent insulinotropic polypeptide induced growth hormone secretion in acromegaly.
Umahara M; Okada S; Ohshima K; Mori M
Endocr J; 2003 Oct; 50(5):643-50. PubMed ID: 14614222
[TBL] [Abstract][Full Text] [Related]
4. KDM1A genotyping and expression in 146 sporadic somatotroph pituitary adenomas.
Chasseloup F; Regazzo D; Tosca L; Proust A; Kuhn E; Hage M; Jublanc C; Mokhtari K; Dalle Nogare M; Avallone S; Ceccato F; Tachdjian G; Salenave S; Young J; Gaillard S; Parker F; Boch AL; Chanson P; Bouligand J; Occhi G; Kamenický P
Eur J Endocrinol; 2024 Feb; 190(2):173-181. PubMed ID: 38330165
[TBL] [Abstract][Full Text] [Related]
5. The GIP/GIPR axis is functionally linked to GH-secretion increase in a significant proportion of
Regazzo D; Losa M; Albiger NM; Terreni MR; Vazza G; Ceccato F; Emanuelli E; Denaro L; Scaroni C; Occhi G
Eur J Endocrinol; 2017 May; 176(5):543-553. PubMed ID: 28179449
[TBL] [Abstract][Full Text] [Related]
6. Preoperative growth hormone response to thyrotropin-releasing hormone and oral glucose tolerance test in acromegaly: a retrospective evaluation of 50 patients.
De Marinis L; Mancini A; Bianchi A; Gentilella R; Valle D; Giampietro A; Zuppi P; Anile C; Maira G; Giustina A
Metabolism; 2002 May; 51(5):616-21. PubMed ID: 11979395
[TBL] [Abstract][Full Text] [Related]
7. The glucose-dependent insulinotropic polypeptide receptor is overexpressed amongst GNAS1 mutation-negative somatotropinomas and drives growth hormone (GH)-promoter activity in GH3 cells.
Occhi G; Losa M; Albiger N; Trivellin G; Regazzo D; Scanarini M; Monteserin-Garcia JL; Fröhlich B; Ferasin S; Terreni MR; Fassina A; Vitiello L; Stalla G; Mantero F; Scaroni C
J Neuroendocrinol; 2011 Jul; 23(7):641-9. PubMed ID: 21554434
[TBL] [Abstract][Full Text] [Related]
8. Value of early postoperative random growth hormone levels and nadir growth hormone levels after oral glucose tolerance testing in acromegaly.
Rotermund R; Burkhardt T; Rohani Z; Jung R; Aberle J; Flitsch J
Growth Horm IGF Res; 2018 Aug; 41():64-70. PubMed ID: 29555234
[TBL] [Abstract][Full Text] [Related]
9. Outpatient assessment of residual growth hormone secretion in treated acromegaly with overnight urinary growth hormone excretion, random serum growth hormone and insulin like growth factor-1.
Parfitt VJ; Flanagan D; Wood P; Leatherdale BA
Clin Endocrinol (Oxf); 1998 Nov; 49(5):647-52. PubMed ID: 10197081
[TBL] [Abstract][Full Text] [Related]
10. Growth hormone responses to oral glucose and intravenous thyrotropin-releasing hormone in acromegalic patients treated by slow-release lanreotide.
Díez JJ; Iglesias P; Gómez-Pan A
J Endocrinol Invest; 2001 May; 24(5):303-9. PubMed ID: 11407648
[TBL] [Abstract][Full Text] [Related]
11. Paradoxical GH Increase During OGTT Is Associated With First-Generation Somatostatin Analog Responsiveness in Acromegaly.
Scaroni C; Albiger N; Daniele A; Dassie F; Romualdi C; Vazza G; Regazzo D; Ferraù F; Barresi V; Maffeis V; Gardiman MP; Cannavò S; Maffei P; Ceccato F; Losa M; Occhi G
J Clin Endocrinol Metab; 2019 Mar; 104(3):856-862. PubMed ID: 30285115
[TBL] [Abstract][Full Text] [Related]
12. Octreotide suppresses the incretin glucagon-like peptide (7-36) amide in patients with acromegaly or clinically nonfunctioning pituitary tumors and in healthy subjects.
Plöckinger U; Holst JJ; Messerschmidt D; Hopfenmüller W; Quabbe HJ
Eur J Endocrinol; 1999 Jun; 140(6):538-44. PubMed ID: 10377503
[TBL] [Abstract][Full Text] [Related]
13. Impact of tumor characteristics and pre- and postoperative hormone levels on hormonal remission following endoscopic transsphenoidal surgery in patients with acromegaly.
Cardinal T; Rutkowski MJ; Micko A; Shiroishi M; Jason Liu CS; Wrobel B; Carmichael J; Zada G
Neurosurg Focus; 2020 Jun; 48(6):E10. PubMed ID: 32480366
[TBL] [Abstract][Full Text] [Related]
14. Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects.
Yanagimachi T; Fujita Y; Takeda Y; Honjo J; Sakagami H; Kitsunai H; Takiyama Y; Abiko A; Makino Y; Kieffer TJ; Haneda M
Mol Metab; 2017 Feb; 6(2):226-231. PubMed ID: 28180064
[TBL] [Abstract][Full Text] [Related]
15. Hypermethylator Phenotype and Ectopic GIP Receptor in GNAS Mutation-Negative Somatotropinomas.
Hage M; Chaligné R; Viengchareun S; Villa C; Salenave S; Bouligand J; Letouzé E; Tosca L; Rouquette A; Tachdjian G; Parker F; Lombès M; Lacroix A; Gaillard S; Chanson P; Kamenický P
J Clin Endocrinol Metab; 2019 May; 104(5):1777-1787. PubMed ID: 30376114
[TBL] [Abstract][Full Text] [Related]
16. Paradoxical GH increase during oral glucose load may predict overall remission in acromegalic patients.
Düğer H; Bostan H; Deryol HY; İmga NN; Uçan B; Çalapkulu M; Hepşen S; Akhanlı P; Gül Ü; Sencar ME; Çakal E; Özdemir Ş; Kızılgül M
Growth Horm IGF Res; 2022 Dec; 67():101501. PubMed ID: 36166917
[TBL] [Abstract][Full Text] [Related]
17. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly.
Carmichael JD; Bonert VS; Mirocha JM; Melmed S
J Clin Endocrinol Metab; 2009 Feb; 94(2):523-7. PubMed ID: 19033371
[TBL] [Abstract][Full Text] [Related]
18. Predicting long-term remission by measuring immediate postoperative growth hormone levels and oral glucose tolerance test in acromegaly.
Kim EH; Oh MC; Lee EJ; Kim SH
Neurosurgery; 2012 May; 70(5):1106-13; discussion 1113. PubMed ID: 22067418
[TBL] [Abstract][Full Text] [Related]
19. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
[TBL] [Abstract][Full Text] [Related]
20. Circulating levels of incretin hormones and amylin in the fasting state and after oral glucose in GH-deficient patients before and after GH replacement: a placebo-controlled study.
Jørgensen JO; Rosenfalck AM; Fisker S; Nyholm B; Fineman MS; Schmitz O; Madsbad S; Holst JJ; Christiansen JS
Eur J Endocrinol; 2000 Nov; 143(5):593-9. PubMed ID: 11078982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
